Curcumin Supplementation and Patients With Type 2 Diabetes
The Effect of Curcumin Supplementation on Anthropometric Indices, Insulin Resistance and Oxidative Stress in Patients With Type 2 Diabetes
1 other identifier
interventional
44
1 country
1
Brief Summary
Diabetes mellitus is the most common endocrine disorder, causes many complications such as micro- and macro-vascular diseases. Various kinds of antidiabetic drugs have been developed, but most of them have side effects. Recently, the use of natural plant products has gained more attention among scientists in order to prevent diabetic vascular complications. Curcumin is a natural yellow product derived from the turmeric rhizome which has shown to be non-toxic and exhibits various bio¬logical activities such as anti-oxidant, anti-inflammatory, anti-carcinogenic, and anti-diabetic effects. Curcumin is effective in reducing glycemic index and hyperlipidemia in rodent models and is relatively inexpensive and safe. Most of the studies conducted on animal model, and just a few of them are on human model. The present study was planned to evaluate the effects of curcumin supplementation The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2015
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2015
CompletedFirst Submitted
Initial submission to the registry
August 19, 2015
CompletedFirst Posted
Study publicly available on registry
August 20, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2016
CompletedFebruary 26, 2019
February 1, 2019
6 months
August 19, 2015
February 24, 2019
Conditions
Outcome Measures
Primary Outcomes (5)
fasting blood sugar
10 weeks
Insulin
10 week
HbA1c
10 week
Homeostatic Model Assessment of Insulin Resistance
10 week
Change in pancreatic B-cell function
10 week
Secondary Outcomes (4)
total capacity antioxidant
10 weeks
Malondialdehyde
10 week
Body mass index
10 week
Waist circumference
10 week
Study Arms (2)
intervention
ACTIVE COMPARATOR500 mg curcumin capsule
control
PLACEBO COMPARATORplacebo
Interventions
Eligibility Criteria
You may qualify if:
- a) Tendency to participate b) Age range of 40-65 c) Suffering from diabetes type 2 ( between 1 to 10 yeares) d) BMI 18/5-30 e) Patients with diabetes who administer oral hypoglycemic agents and do not use
You may not qualify if:
- a) patients with liver diseases b) patients with kidney diseases c) patients with inflammatory diseases d) patients with liver diseases e) Administering herbal agents f) Administering multivitamins and minerals in past 3 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
NNFTRI clinic
Tehran, 19435, Iran
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
August 19, 2015
First Posted
August 20, 2015
Study Start
July 1, 2015
Primary Completion
January 1, 2016
Study Completion
April 1, 2016
Last Updated
February 26, 2019
Record last verified: 2019-02